IL13 and idiopathic pulmonary fibrosis: Tralokinumab is an IL-13 specific human immunoglobulin G4 monoclonal antibody that binds to and neutralizes IL-13, which showed therapeutic advantage in clinical trials involving patients with asthma and idiopathic pulmonary fibrosis.